---
document_datetime: 2023-09-21 18:32:53
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/optimark-epar-procedural-steps-taken-authorisation_en.pdf
document_name: optimark-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5439835
conversion_datetime: 2025-12-19 00:21:45.131823
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  Tyco  Healthcare  Deutschland  GmbH  submitted  on  2  May  2006  an  application  for Marketing Authorisation to the European Medicines Agency (EMEA) for OptiMARK, through the centralised procedure under Article 3 (2) (a) of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMEA/CHMP on 19 December 2005.

The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application

The application submitted is a complete dossier:

composed of administrative information, complete quality data, non-clinical and clinical data based on  applicants'  own  tests  and  studies  and/or  bibliographic  literature  substituting/supporting  certain tests or studies

- The Rapporteur's first Assessment Report was circulated to all CHMP members on 11 August 2006. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 18 July 2006. In accordance with Article 6(3) of Regulation (RC) No 726/2004, the Rapporteur and  Co-Rapporteur  declared  that  they  had  completed  their  assessment  report  in  less  than 80 days.

Scientific Advice: The applicant received Scientific Advice from the CHMP on 27 May 2005. The Scientific Advice pertained to clinical aspects of the dossier. Licensing status: OptiMARK has been given a Marketing Authorisation in Argentina on 26/02/2006, in Australia on 08/12/1999,  in  Brazil  on  25/07/2000,  in  Canada  on  20/12/2000,  in  Chile  in  December  2002,  in Colombia  on  27/06/2001,  in  Ecuador  on  01/09/2005,  in  Guatemala  on  11/08/2004,  in  India  on 01/05/2003,  in  Korea  on  13/09/2005,  in  Mexico  on  08/05/2002,  in  Peru  on  20/02/2003,  in  the Philippines on 14/03/2003, in Singapore on 28/04/2003, in Taiwan on 22/04/2005 and in the USA on 08/12/1999. A new application was filed in the following country: Uruguay. The Rapporteur and Co-Rapporteur appointed by the CHMP were: Rapporteur: Patrick Salmon Co-Rapporteur: Barbara van Zwieten-Boot 2. Steps taken for the assessment of the product · The application was received by the EMEA on 2 May 2006. · The procedure started on 24 May 2006. Medicinal product no longer authorised

- During the meeting on 18-21 September 2006, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 21 September 2006.
- The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 10 January 2007.
- The summary report of the inspection carried out at the following site Mallinckrodt Medical Inc.  -  Parenteral  Plant  -  8800  Durant  Road  -  Raleigh,  North  Carolina  -  USA  between  10-13 October 2006 was issued on 23 November 2006.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 16 February 2007.

<div style=\"page-break-after: always\"></div>

- The Rapporteurs circulated  a  revised  Joint  Assessment  Report  on  Quality  on  the  applicant's responses to D150 Quality questions to all CHMP members on 14 March 2007.
- During the CHMP meeting on 19-22 March 2007, the CHMP agreed on a list of outstanding issues to be addressed in writing and in an oral explanation by the applicant.
- The applicant submitted the responses to the list of outstanding issues on 2 May 2007.
- During the meeting on 21-24 May 2007, the CHMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to OptiMARK on 24 May 2007. The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 22 May 2007.
- The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 23 July 2007.

<!-- image -->